AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases

ISM9546 targets VAV1, a protein previously considered "undruggable" due to its lack of a classic small-molecule binding pocket. The development of ISM9546 as a molecular glue degrader demonstrates how AI-driven platforms like Insilico's Chemistry42 can address challenging biological targets. The platform's integration of generative models and predictive modules enabled multi-objective optimization, balancing efficacy with reduced central nervous system exposure.

Preclinical studies indicate ISM9546's effectiveness, showing sub-nanomolar degradation potency and significant reduction in disease activity in animal models of inflammatory bowel disease (IBD). Histopathological analysis supported these findings, with approximately 60% improvement in pathology scores. The peripherally restricted profile and favorable safety margins observed in toxicity evaluations suggest a potentially well-tolerated treatment option.

This nomination contributes to Insilico's accelerating pipeline, with 11 preclinical candidates in 2026 alone. The company's co-CEO, Feng Ren, states that AI's potential extends beyond conventional small molecules to new therapeutic modalities. This expansion into molecular glue degraders, alongside other modalities, illustrates the broadening application of generative AI in drug discovery to tackle complex mechanisms and deliver new treatment options.